Immunovant Inc Aktie News

Alle klinischen Entwicklungszeitpläne für IMVT-1402 bleiben im Zeitplan, einschließlich laufender Studien bei Morbus Basedow (Graves’ disease, GD), Myasthenia gravis (MG), chronisch inflammatorischer demyelisierender Polyneuropathie (CIDP), schwer zu behandelnder rheumatoider Arthritis (D2T RA), Sjögren-Syndrom (SjD) und kutaner Lupus erythematodes (CLE) Aktueller Kassenbestand bietet finanziel...

Immunovant reports clinically meaningful trial results for its lead drug candidate. That's good news for Roivant Sciences.

Immunovant stock shot to an 18-month high Wednesday on "highly compelling" results for its experimental rheumatoid arthritis treatment.

DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026.

Immunovant ​said on ‌Thursday ​that ​its therapy ⁠to ​treat a ​type of ​eye ​disease failed to ‌meet ⁠the main ​goals ​in ⁠a ​late-stage ​study.

Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.